SYDNEY, Oct 25, 2007 (AsiaPulse via COMTEX) -- Biota Holdings is looking forward to royalties from international druggist GlaxoSmithKline (GSK) for its influenza drug, Relenza, of $A4.5 million ($US4.06 million) for the three months up to September 30.
